Australian biotech Dimerix (ASX: DXB) today revealed it has received the first development milestone payment of 400 million yen (~AU$4.2 million; US$2.7 million) from Japan’ FUSO Pharmaceutical, the exclusive licensee of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan.
Under the FUSO agreement, Dimerix may become eligible to receive further potential success-based development and regulatory milestone payments of up to 3 billion yen (~AU$30.6 million) in further potential development milestones, up to 6.8 billion yen (~AU$69.4 million) in potential sales milestones and tiered royalties from 15% to 20% of DMX 200 net sales in Japan.
Dimerix noted that it now has four high quality partners across multiple territories, providing strong support for Dimerix in advancing and commercializing DMX-200 as a potential new treatment for FSGS. Collectively across all licenses, Dimerix may become eligible for up to ~AU$1.4 billion in total upfront payments and potential milestone payments, plus royalties on net sales. Dimerix noted that it continues to pursue licensing opportunities with potential partners in territories not already licensed including China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze